You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,895,617


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,895,617
Title:Composition and method for treating neurological disease
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA), Porter; Seth (San Carlos, CA), Meyerson; Laurence R. (Las Vegas, NV), Burkoth; Timothy S. (Lake Bluff, IL)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:14/451,273
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,895,617
Patent Claim Types:
see list of patent claims
Use; Composition; Device;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 8,895,617

When analyzing a patent, particularly one like United States Patent 8,895,617, it is crucial to delve into several key aspects, including the patent's scope, claims, and the broader patent landscape. Here’s a detailed breakdown of these elements.

Patent Overview

United States Patent 8,895,617 is a utility patent granted by the U.S. Patent and Trademark Office (USPTO). To understand its scope and claims, one must first identify the invention it protects.

Invention Description

The patent description outlines the invention, its components, and how it functions. This section is critical for understanding the patent's scope and what is protected.

Claims Analysis

Independent and Dependent Claims

Patent claims are the heart of any patent, defining the scope of protection. Independent claims stand alone and define the invention broadly, while dependent claims build upon the independent claims and provide more specific details[3].

  • Independent Claim Length and Count: Research suggests that the length and count of independent claims can be metrics for measuring patent scope. Shorter and fewer independent claims often indicate a narrower scope, which can be associated with a higher probability of grant and a shorter examination process[3].

Claim Language and Scope

The language used in the claims is pivotal. Broader claims may face more scrutiny during the examination process, as they are more likely to be challenged for obviousness or lack of novelty. Narrower claims, on the other hand, may have a smoother path to grant but offer less extensive protection.

Patent Scope and Quality

The scope of a patent is a significant aspect of patent quality debates. Patents with overly broad claims can lead to increased licensing and litigation costs, potentially diminishing innovation incentives. The examination process often narrows the scope of patent claims to ensure clarity and validity[3].

Examination Process

The patent examination process involves a thorough review by the USPTO to ensure that the patent meets the criteria of novelty, non-obviousness, and utility. The process can significantly impact the final scope of the patent claims.

Prior Art and Citation Data

Understanding the prior art cited during the examination process is essential. Tools like the Common Citation Document (CCD) consolidate citation data from multiple offices, helping to visualize the prior art landscape for a patent family[1].

Patent Family and Related Applications

The patent family includes all related applications filed at participating IP offices. Using resources like the Global Dossier, one can access the file histories, classification, and citation data for these applications, providing a comprehensive view of the patent landscape[1].

International Patent Landscape

To fully understand the scope of a patent, it is necessary to look beyond U.S. borders. Searching international patent databases, such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and World Intellectual Property Organization (WIPO), can reveal whether similar inventions have been patented abroad[1].

Patent Term and Adjustments

The patent term can be affected by various factors, including Patent Term Adjustments (PTA) for USPTO delays during prosecution. Understanding these adjustments and how they impact the patent's expiration date is crucial, especially in cases involving obviousness-type double patenting (ODP)[4].

Obviousness-Type Double Patenting (ODP)

ODP analysis is critical to prevent an inventor from securing multiple patents for the same invention with different expiration dates. This analysis must consider the adjusted expiration date of the patent, including any PTA granted[4].

Litigation and Enforcement

The enforceability of a patent is as important as its scope. The presence of a small claims patent court, as proposed by the Administrative Conference of the United States (ACUS), could potentially simplify the litigation process for smaller entities, though this is still under study[5].

Public Search and Resources

Utilizing public search tools like the Patent Public Search, Global Dossier, and resources from Patent and Trademark Resource Centers (PTRCs) can provide comprehensive insights into the patent's scope and the broader patent landscape[1].

Example: Using Patent Public Search

The Patent Public Search tool offers modern interfaces that enhance access to prior art. This tool can be used to search for existing patents and published patent applications, helping to identify similar inventions and understand the competitive landscape.

Key Takeaways

  • Claims Analysis: Independent and dependent claims define the patent's scope, with narrower claims often having a smoother examination process.
  • Patent Scope and Quality: The scope of a patent is crucial for ensuring clarity and validity, with broader claims facing more scrutiny.
  • International Landscape: Searching international patent databases is essential for understanding the global patent landscape.
  • Patent Term Adjustments: PTA and ODP analyses are critical for determining the patent's expiration date and preventing double patenting.
  • Public Resources: Utilizing public search tools and resources from PTRCs and the USPTO can provide comprehensive insights into the patent's scope.

FAQs

Q: How do I search for existing patents similar to US Patent 8,895,617?

A: You can use the Patent Public Search tool or visit the USPTO Public Search Facility to search for existing patents and published patent applications.

Q: What is the significance of independent claim length and count in patent scope?

A: Independent claim length and count can be metrics for measuring patent scope, with shorter and fewer claims often indicating a narrower scope.

Q: How does the Global Dossier help in understanding the patent landscape?

A: The Global Dossier provides access to the file histories, classification, and citation data for related applications filed at participating IP offices, giving a comprehensive view of the patent family.

Q: What is obviousness-type double patenting (ODP), and why is it important?

A: ODP prevents an inventor from securing multiple patents for the same invention with different expiration dates, ensuring that the patent term is not extended unfairly.

Q: Are there any proposed changes to simplify patent litigation for smaller entities?

A: Yes, the ACUS is studying the feasibility of a small claims patent court to simplify the litigation process for smaller entities.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,895,617

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Supernus Pharms GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-001 Aug 24, 2017 AB RX Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS ⤷  Subscribe
Supernus Pharms GOCOVRI amantadine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 208944-002 Aug 24, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS ⤷  Subscribe
Supernus Pharms OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-001 Feb 16, 2018 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF PARKINSON'S DISEASE ⤷  Subscribe
Supernus Pharms OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-001 Feb 16, 2018 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE ⤷  Subscribe
Supernus Pharms OSMOLEX ER amantadine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209410-004 Apr 22, 2020 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF PARKINSON'S DISEASE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,895,617

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2588296 ⤷  Subscribe
European Patent Office 1845968 ⤷  Subscribe
European Patent Office 2623099 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2006058236 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.